Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

61. Use of computed tomographic features in differentiating peritoneal tuberculosis and peritoneal carcinomatosis: a systematic review with meta-analysis

Use of computed tomographic features in differentiating peritoneal tuberculosis and peritoneal carcinomatosis: a systematic review with meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

62. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. (Full text)

Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS).We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic prednisone can safely (...) reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point was the development

2018 NEJM PubMed

63. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study

Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information (...) you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found modest differences between tests in identifying individuals who would go on to develop active tuberculosis, but a two-step approach was the most cost-effective testing option. {{author}} {{($index , , , , , , , , , , , , & . Ibrahim Abubakar 1, * , Ajit Lalvani 2 , Jo Southern 3 , Alice Sitch 4 , Charlotte Jackson 1 , Oluchukwu Onyimadu 5 , Marc Lipman 6 , Jonathan J

2018 NIHR HTA programme

64. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities (Full text)

Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities Poor medication adherence may increase rates of loss to follow-up, disease relapse and drug resistance for individuals with active tuberculosis (TB). While TB programmes have historically used directly observed therapy (DOT) to address adherence, concerns have been raised about the patient burden, ethical limitations, effectiveness in improving treatment outcomes and long

2018 BMJ global health PubMed

65. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India (Full text)

Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India The End TB Strategy envisions a world free of tuberculosis-zero deaths, disease and suffering due to tuberculosis by 2035. This requires reducing the global tuberculosis incidence from >1250 cases per million people to <100 cases per million people within the next two decades. Expanding testing and treatment of tuberculosis infection is critical to achieving this goal. In high-burden countries, like India (...) , the implementation of tuberculosis preventive treatment (TPT) remains a low priority. In this analysis article, we explore potential challenges and solutions of implementing TPT in India. The next chapter in tuberculosis elimination in India will require cost-effective and sustainable interventions aimed at tuberculosis infection. This will require constant innovation, locally driven solutions to address the diverse and dynamic tuberculosis epidemiology and persistent programme monitoring and evaluation. As new

2018 BMJ global health PubMed

66. Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective

Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective Discover Portal Discover Portal Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective Published on 9 November 2015 doi: This NIHR funded systematic review and economic evaluation found that three rapid tests for diagnosing drug resistant tuberculosis were highly accurate (...) health risk of tuberculosis. Share your views on the research. Why was this study needed? A 2014 Public Health England report showed that tuberculosis (TB) rates in the UK continue to be among the highest of West European countries. There were 7,892 cases of TB recorded in the UK in 2013, around 12 per 100,000 people. TB that does not respond to two of the standard treatments, called multidrug resistant TB, is becoming more common in the UK. Between 2004 and 2011, the proportion of cases

2018 NIHR Dissemination Centre

67. What constitutes an effective and efficient package of services for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health

What constitutes an effective and efficient package of services for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health Sally Hargreaves | Kieran Rustage | Laura B Nellums | Jaynaide Powis | James Milburn Santino Severoni | Masoud Dara | Soorej J Puthoopparambil | Jon S Friedland HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 56 What constitutes an effective and efficient package of services (...) for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health, VIIIThe Health Evidence Network The Health Evidence Network (HEN) is an information service for public health decision-makers in the WHO European Region, in action since 2003 and initiated and coordinated by the WHO Regional Office for Europe under the umbrella of the European Health Information Initiative (a multipartner network coordinating all health

2018 WHO Health Evidence Network

68. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. (Full text)

Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. The World Health Organization recommends drug-susceptibility testing of Mycobacterium tuberculosis complex for all patients with tuberculosis to guide treatment decisions and improve outcomes. Whether DNA sequencing can be used to accurately predict profiles of susceptibility to first-line antituberculosis drugs has not been clear.We obtained whole-genome sequences and associated phenotypes of resistance (...) . Among the 4037 phenotypic profiles that were predicted to be pansusceptible, 3952 (97.9%) were correctly predicted.Genotypic predictions of the susceptibility of M. tuberculosis to first-line drugs were found to be correlated with phenotypic susceptibility to these drugs. (Funded by the Bill and Melinda Gates Foundation and others.).

2018 NEJM PubMed

69. Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent Tuberculosis. (Full text)

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. A vaccine to interrupt the transmission of tuberculosis is needed.We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01E tuberculosis vaccine in Kenya, South Africa, and Zambia. Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in a 1:1 ratio) to receive two (...) doses of either M72/AS01E or placebo intramuscularly 1 month apart. Most participants had previously received the bacille Calmette-Guérin vaccine. We assessed the safety of M72/AS01E and its efficacy against progression to bacteriologically confirmed active pulmonary tuberculosis disease. Clinical suspicion of tuberculosis was confirmed with sputum by means of a polymerase-chain-reaction test, mycobacterial culture, or both.We report the primary analysis (conducted after a mean of 2.3 years

2018 NEJM PubMed

70. Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. (Full text)

Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Suboptimal diagnostics for pulmonary tuberculosis (PTB) drives use of 'trial-of-antibiotics (non-tuberculosis)' in an attempt to distinguish PTB patients from those with bacterial lower respiratory tract infection (LRTI). The underlying assumption-that patients with LRTI will report 'response' to broad-spectrum antibiotics, while

2018 Systematic Reviews PubMed

71. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. (PubMed)

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.In this individual patient data meta-analysis, we searched MEDLINE, Embase (...) , and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data

2018 Lancet

72. Handbook on tuberculosis laboratory diagnostic methods in the European Union

Handbook on tuberculosis laboratory diagnostic methods in the European Union TECHNICAL REPORT www.ecdc.europa.eu Handbook on tuberculosis laboratory diagnostic methods in the European Union Updated 2018ECDC TECHNICAL REPORT Handbook on tuberculosis laboratory diagnostic methods in the European Union Updated 2018 ii This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Csaba Ködmön with support from Marieke J. van der Werf, Francis Drobniewski (...) ’ in 2016 and further revised and renamed ‘Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018’ with changes to Chapters 6.7 and 10.4 in 2018 as new scientific evidence became available. Suggested citation: European Centre for Disease Prevention and Control. Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018. Stockholm: ECDC; 2018. Stockholm, August 2018 ISBN 978-92-9498-264-3 doi 10.2900/914169 Catalogue number TQ-03-18

2018 European Centre for Disease Prevention and Control - Technical Guidance

73. European Union Standards for Tuberculosis Care (Full text)

European Union Standards for Tuberculosis Care 1 European Union Standards for Tuberculosis Care 2017 update www.ecdc.europa.euWhere to find ECDC publications Newsletter Subscribe to receive a monthly email about the latest ECDC publications or new print publications based on your areas of interest. http://surveys.publications.europa.eu/formserver/ecdc/subscription.html Link accessible from the ECDC website under ‘Newsletter’. Online www.ecdc.europa.eu Print Order printed copies at the online (...) library for EU publications (EU Bookshop): www.publications.europa.eu/bookshop To access directly all ECDC publications on EU Bookshop: www.europa.eu/!xk84gB To contact us: publications@ecdc.europa.eu Paper ISBN 978-92-9498-248-3 doi: 10.2900/307948 TQ-02-18-860-EN-C PDF ISBN 978-92-9498-247-6 doi: 10.2900/308103 TQ-02-18-860-EN-N1 Introduction 2 Standards for tuberculosis diagnosis 4 Standards for tuberculosis treatment 6 Standards for addressing HIV infection and comorbidities 10 Standards

2018 European Centre for Disease Prevention and Control - Public Health Guidance PubMed

74. Bacterial Factors That Predict Relapse after Tuberculosis Therapy. (PubMed)

Bacterial Factors That Predict Relapse after Tuberculosis Therapy. Approximately 5% of patients with drug-susceptible tuberculosis have a relapse after 6 months of first-line therapy, as do approximately 20% of patients after 4 months of short-course therapy. We postulated that by analyzing pretreatment isolates of Mycobacterium tuberculosis obtained from patients who subsequently had a relapse or were cured, we could determine any correlations between the minimum inhibitory concentration (MIC (...) ) of a drug below the standard resistance breakpoint and the relapse risk after treatment.Using data from the Tuberculosis Trials Consortium Study 22 (development cohort), we assessed relapse and cure isolates to determine the MIC values of isoniazid and rifampin that were below the standard resistance breakpoint (0.1 μg per milliliter for isoniazid and 1.0 μg per milliliter for rifampin). We combined this analysis with clinical, radiologic, and laboratory data to generate predictive relapse models, which

2018 NEJM

75. Xpert<sup>®</sup> MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. (Full text)

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Tuberculosis (TB) is the world's leading infectious cause of death. Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over half a million people were newly diagnosed with rifampicin-resistant TB in 2016. Xpert® MTB/RIF (Xpert) is a World Health Organization (WHO)-recommended, rapid, automated, nucleic acid amplification assay that is used widely for simultaneous (...) detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum specimens. This Cochrane Review assessed the accuracy of Xpert in extrapulmonary specimens.To determine the diagnostic accuracy of Xpert a) for extrapulmonary TB by site of disease in people presumed to have extrapulmonary TB; and b) for rifampicin resistance in people presumed to have extrapulmonary TB.We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web

2018 Cochrane PubMed

76. Drug-resistant tuberculosis: is India ready for the challenge? (Full text)

Drug-resistant tuberculosis: is India ready for the challenge? 30116597 2018 11 14 2059-7908 3 4 2018 BMJ global health BMJ Glob Health Drug-resistant tuberculosis: is India ready for the challenge? e000971 10.1136/bmjgh-2018-000971 Chatterjee Soumya S 0000-0003-3628-3738 Division of Infectious Diseases, Allergy and Immunology, Saint Louis University, St Louis, Missouri, USA. Poonawala Husain H 0000-0003-4334-7226 Department of Immunology, National Institute for Research in Tuberculosis (...) , Chennai, Tamil Nadu, India. Jain Yogesh Y Jan Swasthya Sahyog, Ganiyari, Chhattisgarh, India. eng Journal Article 2018 08 10 England BMJ Glob Health 101685275 2059-7908 epidemiology health policy health systems public health tuberculosis Competing interests: None declared. 2018 05 23 2018 07 01 2018 07 02 2018 8 18 6 0 2018 8 18 6 0 2018 8 18 6 1 epublish 30116597 10.1136/bmjgh-2018-000971 bmjgh-2018-000971 PMC6089296 PLoS Med. 2009 Sep;6(9):e1000146 19753109 Nat Genet. 2017 Mar;49(3):395-402 28092681

2018 BMJ global health PubMed

77. Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis (Full text)

Research on the value of the T cell spot test for tuberculosis for the diagnosis of lung cancer combined with pulmonary tuberculosis This study was conducted to investigate the value of the T cell spot test for tuberculosis (T-SPOT.TB) for the diagnosis of patients with lung cancer combined with pulmonary tuberculosis (LCTB).Thirty-six patients diagnosed with LCTB who received treatment at Shandong Provincial Chest Hospital from September 2014 to 2017 were randomly chosen and enrolled

2018 Thoracic cancer PubMed

78. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. (Full text)

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. A 9-month regimen of isoniazid can prevent active tuberculosis in persons with latent tuberculosis infection. However, the regimen has been associated with poor adherence rates and with toxic effects.In an open-label trial conducted in nine countries, we randomly assigned adults with latent tuberculosis infection to receive treatment with a 4-month regimen of rifampin or a 9-month regimen of isoniazid (...) for the prevention of confirmed active tuberculosis within 28 months after randomization. Noninferiority and potential superiority were assessed. Secondary outcomes included clinically diagnosed active tuberculosis, adverse events of grades 3 to 5, and completion of the treatment regimen. Outcomes were adjudicated by independent review panels.Among the 3443 patients in the rifampin group, confirmed active tuberculosis developed in 4 and clinically diagnosed active tuberculosis developed in 4 during 7732 person

2018 NEJM PubMed

79. Tuberculosis

Tuberculosis Top results for tuberculosis - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for tuberculosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

80. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review (Full text)

International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due to residual lung damage. Yet, the WHO End TB strategy does not mention post-TB chronic lung disorders (PTBLDs) and programmatic interventions to address PTBLD are lacking. This study assessed the scope of current guidelines and evidence on PTBLD to inform policy and research action.A systematic

2018 BMJ global health PubMed